Ms. Findling has worked with great passion in the oncology field for 16 years. She has been involved in many global Phase I – Phase III studies with her primary focus being early-phase clinical trials (Phase I/II). Across this work, some of the many oncology tumor types she has worked with are prostate cancer, hematology, multiple myeloma, lymphoma, all comers, bladder cancer, non-small cell lung carcinoma, triple negative breast cancer and other types of breast cancer, head and neck cancer, pancreatic cancer, ovarian cancer, renal cell carcinoma, colorectal cancer and other solid tumors. Her most recent focus has been in CAR-T and Immunotherapy treatments.
For the last 5 years, Amy has been a dedicated global project director focused on the execution of clinical trials in oncology. She has led large teams to success on very complex, global projects, ensuring that enrollment is met despite competing trials and that databases are locked on time. She is well versed in successfully overcoming the challenges of executing clinical trials in this complex therapeutic area. And, her many years dedicated to oncology research has given Ms. Findling an in-depth knowledge of disease assessment (including for immunotherapy treatments), common risks, various protocols designs, unique procedures and the associated trainings required, end points, CRF development across many tumor types and data collection requirements.
“We all, in one way or another, have been touched by cancer, unfortunately. Oncology has an ongoing, enormous need for research and treatments, from new chemotherapies, immunotherapies, CAR-T treatments, Stem Cell Treatment, just to name a few. This ongoing need for continual advancement in oncology, as well as the opportunity to be part of bringing to the market future, successful and innovative treatments, is what drives me.”